AltheaDx is a commercial stage personalized medicine company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx\'s IDgenetix pharmacogenetics product testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/14/15 | $30,000,000 |
Ally Bridge Group ALMA Life Sciences WuXi Healthcare Ventures WuXi PharmaTech | undisclosed | |
| 04/26/17 | $27,000,000 | Series D |
